Eli Lilly’s Phase 3 SEQUOIA trial fails to meet primary endpoint
Category: #health  | By Mateen Dalal  | Date: 2019-10-18 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly’s Phase 3 SEQUOIA trial fails to meet primary endpoint

Metastatic pancreatic cancer (MPC) is one of the most fatal cancers in the world. Pancreatic cancer is slated to be the third leading cause of cancer death in the U.S. and is expected to become the second leading cause of cancer-related death over the coming years. As this is an aggressive cancer, there is a dire need for new treatments to improve clinical outcomes for pancreatic cancer patients.

Eli Lilly and Company has reportedly declared top-line results from its Phase 3 SEQUOIA trial assessing pegilodecakin plus FOLFOX compared to FOLFOX alone in patients who are suffering from metastatic pancreatic cancer whose disease has progressed on one prior gemcitabine-containing regimen. However, the clinical trial failed to meet its primary endpoint of overall survival.

Sources close to the study cite that the most common Grade 3/4 adverse events happening at a higher rate (>5% difference) during SEQUOIA clinical trial were thrombocytopenia, fatigue, neutropenia, and anemia. In-depth safety and efficiency results would be presented at future medical meetings.

Maura Dickler, Vice President, Late Phase Development, Lilly Oncology, said that pancreatic cancer is one most difficult cancer to treat and there had been very few treatment advancements in the later-line metastatic setting.

The company is disappointed by the outcome of this clinical trial, however, is grateful to the patients, researchers, and investigators who took part in it. Dickler added that the company will be focusing on upcoming clinical trial results in lung cancer, taking lessons from these studies and would understand pegilodecakin's novel mechanism of action in cancer immunotherapy in a better way.

Reports cite that, for the next stage of pegilodecakin's clinical trial, Eli Lilly is focusing on conducting studies in NSCLC and assessing biomarkers for the next stage of pegilodecakin's clinical development. The company will also be focusing on other tumor types like renal cell carcinoma where molecules had shown positive activity.

Source Credit - https://investor.lilly.com/news-releases/news-release-details/lilly-announces-phase-3-study-patients-metastatic-pancreatic

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Hyundai Motor Company & Advent sign JDA to develop fuel cell technology

Hyundai Motor Company & Advent sign JDA to develop fuel cell technology

By Mateen Dalal

Hyundai Motor Company and Advent Technologies have entered into a joint development agreement, following the assessment of Advent’s Proprietary Membrane Electrode Assembly (MEA) technology. The evaluation was focused on the ability of Advent&rs...

Intellect chooses IHH Healthcare to devise mental health programs

Intellect chooses IHH Healthcare to devise mental health programs

By Mateen Dalal

Intellect, a leading mental health platform located in Singapore, has reportedly announced a partnership with IHH Healthcare, which is Asia’s largest private healthcare group. The main objective of the partnership is to introduce and customize ...

Dyson compensates employees with onetime payment in absence of bonus

Dyson compensates employees with onetime payment in absence of bonus

By Mateen Dalal

Dyson, a British company renowned for its innovative vacuum cleaners, hair dryers and other products, is reportedly offering a majority of the staff at its Singapore headquarters a one-time payment, in recognition of their exceptional contribution. ...